Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets

[1]  P. Jenner,et al.  L-Dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations , 2001, Psychopharmacology.

[2]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[3]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.

[4]  Martin Lévesque,et al.  Organization of the basal ganglia: the importance of axonal collateralization , 2000, Trends in Neurosciences.

[5]  D. Brooks,et al.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.

[6]  D. D. Di Monte,et al.  Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model , 2000, Movement disorders : official journal of the Movement Disorder Society.

[7]  J A Obeso,et al.  Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. , 2000, Annals of neurology.

[8]  P. Jenner,et al.  Alterations in preproenkephalin and adenosine‐2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with l‐DOPA , 2000, The European journal of neuroscience.

[9]  R. Marconi,et al.  Pergolide monotherapy in the treatment of early PD , 1999, Neurology.

[10]  T. Di Paolo,et al.  Differential Regulation of Striatal Preproenkephalin and Preprotachykinin mRNA Levels in MPTP‐Lesioned Monkeys Chronically Treated with Dopamine D1 or D2 Receptor Agonists , 1999, Journal of neurochemistry.

[11]  J. Brotchie,et al.  Effect of Repeated l -DOPA, Bromocriptine, or Lisuride Administration on Preproenkephalin-A and Preproenkephalin-B mRNA Levels in the Striatum of the 6-Hydroxydopamine-Lesioned Rat , 1999, Experimental Neurology.

[12]  A. Björklund,et al.  L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA , 1998, The European journal of neuroscience.

[13]  K. Fuxe,et al.  Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia 1 Published on the World Wide Web on 12 January 1998. 1 , 1998, Brain Research Reviews.

[14]  P. Jenner,et al.  Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys , 1998, Annals of neurology.

[15]  P. Jenner,et al.  De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmoset , 1998, Movement disorders : official journal of the Movement Disorder Society.

[16]  Sergi Ferré,et al.  Adenosine–dopamine receptor–receptor interactions as an integrative mechanism in the basal ganglia , 1997, Trends in Neurosciences.

[17]  P. Sokoloff,et al.  Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Brotchie,et al.  Enhancement of the Behavioral Response to Apomorphine Administration Following Repeated Treatment in the 6-Hydroxydopamine-Lesioned Rat Is Temporally Correlated with a Rise in Striatal Preproenkephalin-B, but Not Preproenkephalin-A, Gene Expression , 1997, Experimental Neurology.

[19]  O. Hassani,et al.  Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states , 1997, Neuroscience.

[20]  R. Mayfield,et al.  Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: Evidence for an A2a/D2 receptor interaction in globus pallidus , 1996, Synapse.

[21]  P. Jenner,et al.  Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus) , 1995, Movement disorders : official journal of the Movement Disorder Society.

[22]  E. Hirsch,et al.  Effects of l-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum , 1995, Neuroscience.

[23]  C. Marsden,et al.  L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. , 1995, Brain research. Molecular brain research.

[24]  C. Marsden,et al.  Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease , 1995, Neuroscience.

[25]  P. Jenner,et al.  Chronicl-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat , 1995, Neuroscience.

[26]  C. Marsden,et al.  Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset. , 1995, European journal of pharmacology.

[27]  M. Piercey,et al.  Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. , 1995, The Journal of pharmacology and experimental therapeutics.

[28]  A. Parent,et al.  Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys , 1994, Neuroreport.

[29]  S. Augood,et al.  Adenosine A2a receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a co-expression study. , 1994, Brain research. Molecular brain research.

[30]  A. Flaherty,et al.  Input-output organization of the sensorimotor striatum in the squirrel monkey , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[31]  J. Brotchie,et al.  On the Role of Enkephalin Cotransmission in the GABAergic Striatal Efferents to the Globus Pallidus , 1994, Experimental Neurology.

[32]  T J Furlong,et al.  Molecular characterization of a human brain adenosine A2 receptor. , 1992, Brain research. Molecular brain research.

[33]  E. M. Adler,et al.  Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. , 1992, Brain research. Molecular brain research.

[34]  J. Palacios,et al.  Adenosine A2 receptors: Selective localization in the human basal ganglia and alterations with disease , 1991, Neuroscience.

[35]  U. Rinne.  New strategies in the treatment of early Parkinson's disease , 1991, Acta neurologica Scandinavica. Supplementum.

[36]  S. Schiffmann,et al.  Distribution of adenosine A2 receptor mRNA in the human brain , 1991, Neuroscience Letters.

[37]  S. Schiffmann,et al.  Striatal Restricted Adenosine A2 Receptor (RDC8) Is Expressed by Enkephalin but Not by Substance P Neurons: An In Situ Hybridization Histochemistry Study , 1991, Journal of neurochemistry.

[38]  C. Gerfen,et al.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.

[39]  M. Delong,et al.  Primate models of movement disorders of basal ganglia origin , 1990, Trends in Neurosciences.

[40]  J G Nutt,et al.  Levodopa‐induced dyskinesia , 1990, Neurology.

[41]  S. Augood,et al.  Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys. , 1989, Brain research. Molecular brain research.

[42]  T. Chase,et al.  Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease , 1987, Annals of neurology.

[43]  T. Bonner,et al.  Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[44]  G. Fink,et al.  cDNA sequence of human β‐preprotachykinin, the common precursor to substance P and neurokinin A , 1986, FEBS letters.

[45]  T. Paolo,et al.  Chronic treatment withl-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding , 1986, Brain Research.

[46]  S. Snyder,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[47]  T. Miyata,et al.  Isolation and structural organization of the human preproenkephalin B gene , 1982, Nature.

[48]  Peter H. Seeburg,et al.  Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA , 1982, Nature.

[49]  A. Lees,et al.  Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. , 1981, Journal of neurology, neurosurgery, and psychiatry.

[50]  T. Shindou,et al.  Physiology of Adenosine Receptors in the Striatum: Regulation of Striatal Projection Neurons , 2000 .

[51]  J. Obeso,et al.  Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. , 2000, Neurology.

[52]  P. Jenner,et al.  Adenosine receptors and Parkinson's disease , 1999 .

[53]  J. Jankovic,et al.  A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease , 1994 .

[54]  J. Cadet,et al.  Quantitative in situ hybridization evidence for differential regulation of proenkephalin and dopamine D2 receptor mRNA levels in the rat striatum: effects of unilateral intrastriatal injections of 6-hydroxydopamine. , 1992, Brain research. Molecular brain research.

[55]  A. Crossman,et al.  A hypothesis on the pathophysiological mechanisms that underlie levodopa‐ or dopamine agonist‐induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment , 1990, Movement disorders : official journal of the Movement Disorder Society.

[56]  J. Montastruc,et al.  [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results]. , 1982, Revue neurologique.

[57]  J. D. Parkes,et al.  Fluctuations of disability in Parkinson's disease – clinical aspects , 1981 .